Additionally, SUMOylation (SUMO) was identified as a regulator of PPARγ activity in our PPI analysis, offering a potential strategy for developing safer drugs for treating type 2 diabetes by inhibiting insulin-sensitizing activity without affecting adiposity in mice [45]. This evidence concerns the gene PPARG and type 2 diabetes mellitus.